

Giovanni G1 Lapadula

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6428200/publications.pdf>

Version: 2024-02-01

160
papers

6,538
citations

53794

45
h-index

74163

75
g-index

163
all docs

163
docs citations

163
times ranked

7736
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases. <i>Journal of Rheumatology</i> , 2021, 48, 48-57.	2.0	7
2	Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. <i>Joint Bone Spine</i> , 2021, 88, 105062.	1.6	14
3	Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry. <i>Clinical Rheumatology</i> , 2021, 40, 4039-4047.	2.2	3
4	Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry. <i>Archives of Rheumatology</i> , 2020, 35, 163-169.	0.9	3
5	Psoriatic arthritis and obesity: the role of anti-IL-12/IL-23 treatment. <i>Clinical Rheumatology</i> , 2019, 38, 2355-2362.	2.2	15
6	Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study. <i>European Journal of Internal Medicine</i> , 2019, 66, 57-61.	2.2	9
7	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , 2019, 10, 296.	3.5	35
8	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1553-1570.	5.6	75
9	Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?. <i>Clinical Drug Investigation</i> , 2019, 39, 565-575.	2.2	8
10	Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2019, 29, 895-902.	1.8	9
11	Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis. <i>Clinical and Experimental Immunology</i> , 2019, 196, 123-138.	2.6	27
12	Factors predicting early discontinuation of methotrexate as a first-line treatment for rheumatoid arthritis in Italy: Results from the GISEA registry. <i>Indian Journal of Rheumatology</i> , 2019, 14, 271.	0.4	1
13	Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 649-655.	0.8	10
14	Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 762-767.	0.8	10
15	Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE). <i>Clinical Rheumatology</i> , 2018, 37, 667-675.	2.2	28
16	The UltraSound-Clinical ARthritis Activity (US-CLARA) index: Properties of a new composite disease activity index for rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 619-629.	3.4	9
17	Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. <i>Joint Bone Spine</i> , 2018, 85, 455-459.	1.6	14
18	Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment. <i>Mediators of Inflammation</i> , 2018, 2018, 1-7.	3.0	30

#	ARTICLE	IF	CITATIONS
19	Patients’, physicians’, nurses’, and pharmacists’ preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases. Patient Preference and Adherence, 2018, Volume 12, 2153-2168.	1.8	15
20	Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors. Journal of Clinical Medicine, 2018, 7, 504.	2.4	61
21	Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. Rheumatology, 2018, 57, vii42-vii53.	1.9	24
22	The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts. Autoimmunity Reviews, 2018, 17, 1251-1258.	5.8	2
23	Orofacial Manifestations and Temporomandibular Disorders of Sjögren Syndrome: An Observational Study. International Journal of Medical Sciences, 2018, 15, 475-483.	2.5	25
24	Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clinical Rheumatology, 2018, 37, 2233-2240.	2.2	64
25	Prise en charge de lâ€™infection par le virus de lâ€™hépatite B chez les patients atteints de polyarthrite rhumatoïde: conférence de consensus italienne. Revue Du Rhumatisme (Edition Francaise), 2018, 85, 115-120.	0.0	0
26	Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers. Israel Medical Association Journal, 2018, 20, 438-441.	0.1	7
27	Epidemiological profile of non-infectious uveitis from the rheumatologist's perspective: a survey from two tertiary referral centres in Italy. Clinical and Experimental Rheumatology, 2018, 36, 68-73.	0.8	15
28	Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2017, 47, 108-114.	3.4	37
29	Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease. Clinical Rheumatology, 2017, 36, 2063-2069.	2.2	36
30	Comparing Originator Biologics and Biosimilars: A Review of the Relevant Issues. Clinical Therapeutics, 2017, 39, 1026-1039.	2.5	23
31	Polyarthrite rhumatoïde: réponse clinique précoce sous certolizumab prédictive d'une faible activité de la maladie à un an en situation de coévaluation du registre italien GISEA. Revue Du Rhumatisme (Edition Francaise), 2017, 84, 511-515.	0.0	0
32	Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. Joint Bone Spine, 2017, 84, 525-530.	1.6	15
33	No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan. International Journal of Rheumatic Diseases, 2017, 20, 90-96.	1.9	4
34	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. Frontiers in Pharmacology, 2017, 8, 369.	3.5	89
35	Update on the Medical Management of Gastrointestinal Behçet's Disease. Mediators of Inflammation, 2017, 2017, 1-11.	3.0	16
36	Cytokine Signatures in Mucocutaneous and Ocular Behçet's Disease. Frontiers in Immunology, 2017, 8, 200.	4.8	50

#	ARTICLE	IF	CITATIONS
37	A Case of Osteonecrosis of the Jaw in a Patient with Crohn's Disease Treated with Infliximab. <i>American Journal of Case Reports</i> , 2017, 18, 1351-1356.	0.8	28
38	Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 93-97.	0.8	7
39	Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 660-665.	0.8	5
40	Ustekinumab efficacy and safety in mucocutaneous multi-refractory Behçet's disease. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 108, 130-131.	0.8	5
41	Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 1018-1028.	0.8	8
42	Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 103-109.	0.9	93
43	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 163-169.	0.9	82
44	Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: results by Italian DELphi in psoriatic Arthritis (IDEA). <i>Reumatismo</i> , 2016, 68, 126-136.	0.9	15
45	Orofacial Manifestations and Temporomandibular Disorders of Systemic Scleroderma: An Observational Study. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1189.	4.1	71
46	A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2016, 7, 380.	3.5	72
47	Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1743-1748.	0.9	68
48	Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. <i>Clinical Rheumatology</i> , 2016, 35, 1683-1689.	2.2	83
49	Early clinical response predicts low disease activity at one year in rheumatoid arthritis patients on treatment with certolizumab in real-life settings. An appraisal of the Italian registry GISEA. <i>Joint Bone Spine</i> , 2016, 83, 721-725.	1.6	8
50	Management of Small Vessel Vasculitides. <i>Current Rheumatology Reports</i> , 2016, 18, 36.	4.7	9
51	Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. <i>Clinical Rheumatology</i> , 2016, 35, 2649-2656.	2.2	19
52	Effective tumour necrosis factor-blocking therapy reduces reactive oxygen metabolite level in rheumatoid arthritis. <i>Journal of International Medical Research</i> , 2016, 44, 28-32.	1.0	5
53	Use of ultrasound in treatment decisions for patients with rheumatoid arthritis: an observational study in Italy. <i>Clinical Rheumatology</i> , 2016, 35, 1923-1929.	2.2	4
54	PFAPA syndrome and Behçet's disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists. <i>Clinical Rheumatology</i> , 2016, 35, 501-505.	2.2	28

#	ARTICLE	IF	CITATIONS
55	Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy. <i>Autoimmunity Reviews</i> , 2016, 15, 447-450.	5.8	54
56	Longterm Clinical Outcomes in 420 Patients with Psoriatic Arthritis Taking Anti-tumor Necrosis Factor Drugs in Real-world Settings. <i>Journal of Rheumatology</i> , 2016, 43, 911-917.	2.0	19
57	Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 19-23.	2.2	10
58	Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1285-1292.	0.9	56
59	Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study. <i>Clinical Rheumatology</i> , 2016, 35, 1281-1286.	2.2	95
60	Comment on "Tumor necrosis factor- α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study". <i>Clinical Rheumatology</i> , 2016, 35, 839-840.	2.2	1
61	Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. <i>PLoS ONE</i> , 2016, 11, e0163894.	2.5	158
62	Changes in anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes serum levels in patients with rheumatoid arthritis following treatment with different biological drugs. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 424-9.	0.8	11
63	Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 531-8.	0.8	23
64	Do dermatomyositis and polymyositis affect similar thigh muscles? A comparative MRI-based study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 1098-1100.	0.8	5
65	Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1150-1154.	3.0	42
66	Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behcet's Disease. <i>Medicine (United States)</i> , 2015, 94, e1858.	1.0	31
67	Refractory knee giant cell tumor of the synovial membrane treated with intra-articular injection of Infliximab: a case series and review of the literature. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 908-912.	1.9	2
68	Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M <i>TNFRSF1A</i> variant. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 473-475.	1.9	5
69	Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. <i>Hepatology</i> , 2015, 62, 40-46.	7.3	82
70	Recovery of Barium Swallow Radiographic Abnormalities in a Patient With Dermatomyositis and Severe Dysphagia After High-Dose Intravenous Immunoglobulins. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 227.	0.9	4
71	Coexistence of axial spondyloarthritis and thromboangiitis obliterans in a young woman. <i>Reumatismo</i> , 2015, 67, 17-20.	0.9	1
72	Erasmus syndrome in a marble worker. <i>Reumatismo</i> , 2015, 67, 116-122.	0.9	15

#	ARTICLE	IF	CITATIONS
73	Correlation between serum amyloid-A and serum levels of proinflammatory cytokines in patients with Behçet's disease. <i>Pediatric Rheumatology</i> , 2015, 13, .	2.1	3
74	Influence of TNF- α inhibition on oxidative stress of rheumatoid arthritis patients. <i>Reumatismo</i> , 2015, 67, 97-102.	0.9	12
75	Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives. <i>Mediators of Inflammation</i> , 2015, 2015, 1-10.	3.0	22
76	Interleukin-1 as a Common Denominator from Autoinflammatory to Autoimmune Disorders: Premises, Perils, and Perspectives. <i>Mediators of Inflammation</i> , 2015, 2015, 1-21.	3.0	79
77	Proinflammatory Cytokines and Antiskin Autoantibodies in Patients With Inherited Epidermolysis Bullosa. <i>Medicine (United States)</i> , 2015, 94, e1528.	1.0	51
78	Two-year survival rates of anti-TNF- α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA. <i>Scandinavian Journal of Rheumatology</i> , 2015, 44, 192-199.	1.1	30
79	Obesity reduces the drug survival of second line biological drugs following a first TNF- α inhibitor in rheumatoid arthritis patients. <i>Joint Bone Spine</i> , 2015, 82, 187-191.	1.6	58
80	L'obésité diminue le maintien thérapeutique des traitements biologiques de seconde ligne après l'arrêt d'un anti-TNF de première ligne au cours de la polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition) Tj ET</i> 2015, 41, 100-105 / Overlo	0.4	0
81	Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. <i>Rheumatology</i> , 2015, 54, 792-797.	1.9	67
82	Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1124-1131.	0.9	96
83	Role of nerve growth factor and tropomyosin receptor kinase A in the pathogenesis of osteoarthritis. Might nerve growth factor be the link intertwining obesity and osteoarthritis?. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e70-e70.	0.9	2
84	Early-onset sarcoidosis caused by a rare CARD15/NOD2 de novo mutation and responsive to infliximab: a case report with long-term follow-up and review of the literature. <i>Clinical Rheumatology</i> , 2015, 34, 391-395.	2.2	25
85	Correlation between serum levels of IL-15 and IL-17 in patients with idiopathic inflammatory myopathies. <i>Scandinavian Journal of Rheumatology</i> , 2015, 44, 224-228.	1.1	22
86	Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease. <i>Autoimmunity Reviews</i> , 2015, 14, 1-9.	5.8	79
87	Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab. <i>Clinical Rheumatology</i> , 2015, 34, 1141-1143.	2.2	51
88	Position paper of Italian rheumatologists on the use of biosimilar drugs. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 1-4.	0.8	22
89	Five-year survival on infliximab in rheumatoid arthritis patients: analysis from an Italian registry (GISEA) by different calendar years. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 524-30.	0.8	2
90	Possible interplay between interleukin-15 and interleukin-17 into the pathogenesis of idiopathic inflammatory myopathies. <i>Reumatismo</i> , 2014, 66, 215-223.	0.9	5

#	ARTICLE	IF	CITATIONS
91	A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy. <i>Reumatismo</i> , 2014, 65, 298.	0.9	4
92	Intra-articular therapy with tumor necrosis factor- α antagonists: an update. <i>Reumatismo</i> , 2014, 65, 257.	0.9	9
93	Untangling the Web of Systemic Autoinflammatory Diseases. <i>Mediators of Inflammation</i> , 2014, 2014, 1-15.	3.0	25
94	The Role of Tumour Necrosis Factor in the Pathogenesis of Immune-Mediated Diseases. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 1-10.	2.1	69
95	Adalimumab in the Treatment of Immune-Mediated Diseases. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 33-48.	2.1	65
96	Anti-TNF Agents as Therapeutic Choice in Immune-Mediated Inflammatory Diseases: Focus on Adalimumab. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 11-32.	2.1	50
97	Lipid Profile of Rheumatoid Arthritis Patients Treated with Anti-Tumor Necrosis Factor- α Drugs Changes According to Disease Activity and Predicts Clinical Response. <i>Drug Development Research</i> , 2014, 75, S77-80.	2.9	13
98	Retinal Vessels Thrombosis as Onset Manifestation of Systemic Sclerosis: 3 Clinical Cases. <i>Journal of Rheumatology</i> , 2014, 41, 2495-2496.	2.0	5
99	High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register. <i>Clinical Rheumatology</i> , 2014, 33, 31-37.	2.2	10
100	Update on laser-evoked potential findings in fibromyalgia patients in light of clinical and skin biopsy features. <i>Journal of Neurology</i> , 2014, 261, 461-472.	3.6	61
101	The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. <i>Autoimmunity Reviews</i> , 2014, 13, 751-755.	5.8	67
102	Safety of Etanercept and Methotrexate in Patients with Rheumatoid Arthritis and Hepatitis C Virus Infection: A Multicenter Randomized Clinical Trial. <i>Journal of Rheumatology</i> , 2014, 41, 286-292.	2.0	47
103	Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register. <i>Joint Bone Spine</i> , 2014, 81, 508-512.	1.6	21
104	Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e31-e31.	0.9	8
105	Diagnosis of Latent Tuberculosis and Prevention of Reactivation in Rheumatic Patients Receiving Biologic Therapy: International Recommendations. <i>Journal of rheumatology Supplement</i> , The, 2014, 91, 41-46.	2.2	61
106	Serum amyloid-A in Behçet's disease. <i>Clinical Rheumatology</i> , 2014, 33, 1165-1167.	2.2	14
107	Efficacy and Safety of Certolizumab Pegol in Rheumatoid Arthritis: Meeting Rheumatologists' Requirements in Routine Clinical Practice. <i>BioDrugs</i> , 2014, 28, 25-37.	4.6	4
108	Different switching rate of anti-TNF- α drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life. <i>Joint Bone Spine</i> , 2014, 81, 458-459.	1.6	6

#	ARTICLE	IF	CITATIONS
109	Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF- $\hat{\pm}$ therapy. Scandinavian Journal of Rheumatology, 2013, 42, 41-44.	1.1	29
110	Obesity and reduction of the response rate to anti- $\hat{\pm}$ tumor necrosis factor $\hat{\pm}$ in rheumatoid arthritis: An approach to a personalized medicine. Arthritis Care and Research, 2013, 65, 94-100.	3.4	170
111	Old and New Antirheumatic Drugs and the Risk of Hepatotoxicity. Therapeutic Drug Monitoring, 2012, 34, 622-628.	2.0	28
112	The Inhibitor of Costimulation of T Cells: Abatacept. Journal of rheumatology Supplement, The, 2012, 89, 100-102.	2.2	29
113	Longterm Retention of Tumor Necrosis Factor- $\hat{\pm}$ Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors. Journal of Rheumatology, 2012, 39, 1179-1184.	2.0	87
114	Bosentan fosters microvascular de-remodelling in systemic sclerosis. Clinical Rheumatology, 2012, 31, 1723-1725.	2.2	50
115	Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmunity Reviews, 2012, 12, 225-229.	5.8	146
116	Rituximab treatment for Sjogren syndrome-associated non-Hodgkin- $\hat{\pm}$ lymphoma: case series. Rheumatology International, 2012, 32, 3281-3284.	3.0	7
117	Biosimilars in rheumatology: pharmacological and pharmaco-economic issues. Clinical and Experimental Rheumatology, 2012, 30, S102-6.	0.8	19
118	Chemerin/ChemR23 pathway: a system beyond chemokines. Arthritis Research and Therapy, 2011, 13, 104.	3.5	28
119	Laser-Evoked Potentials Habituation in Fibromyalgia. Journal of Pain, 2011, 12, 116-124.	1.4	101
120	Prevalence of anti-histone antibodies, their clinical significance and correlation with other autoantibodies in a cohort of Italian scleroderma patients. Autoimmunity Highlights, 2011, 2, 29-33.	3.9	6
121	Obesity and Inflammation $\hat{\pm}$ Targets for OA Therapy. Current Drug Targets, 2010, 11, 586-598.	2.1	82
122	Digital laser doppler flowmetry may discriminate $\hat{\pm}$ limited $\hat{\pm}$ from $\hat{\pm}$ diffuse $\hat{\pm}$ systemic sclerosis. Microvascular Research, 2010, 80, 221-226.	2.5	15
123	Response of Cartilage Oligomeric Matrix Protein to Monoclonal Antibody Drugs in Patients with Rheumatoid Arthritis. Laboratory Medicine, 2009, 40, 645-650.	1.2	1
124	Intra-articular clodronate for the treatment of knee osteoarthritis: dose ranging study vs hyaluronic acid. Rheumatology, 2009, 48, 773-778.	1.9	37
125	EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Annals of the Rheumatic Diseases, 2009, 68, 620-628.	0.9	559
126	Gastrointestinal symptoms and motility disorders in patients with systemic scleroderma. BMC Gastroenterology, 2008, 8, 7.	2.0	55

#	ARTICLE	IF	CITATIONS
127	Extracorporeal shock waves down-regulate the expression of interleukin-10 and tumor necrosis factor-alpha in osteoarthritic chondrocytes. <i>BMC Musculoskeletal Disorders</i> , 2008, 9, 16.	1.9	38
128	Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1121-1126.	0.9	55
129	Functional Impairments of Microcirculation in HIV-Positive Patients: A Laser Doppler Fluxometry-Based Investigation. <i>HIV Clinical Trials</i> , 2008, 9, 428-433.	2.0	6
130	Phenotype of chondrocytes in osteoarthritis. <i>Biorheology</i> , 2008, 45, 411-413.	0.4	9
131	Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. <i>Journal of Rheumatology</i> , 2008, 35, 1944-9.	2.0	82
132	Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 754-763.	0.9	739
133	Clinical outcomes of bosentan in pulmonary arterial hypertension do not correlate with levels of TIMPs. <i>European Journal of Clinical Investigation</i> , 2006, 36, 73-77.	3.4	10
134	Cutaneous lesions as presenting symptoms of primary biliary cirrhosis: an undifferentiated connective tissue disease-like onset. <i>Clinical Rheumatology</i> , 2006, 25, 919-922.	2.2	4
135	Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 249-252.	0.9	46
136	Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. <i>Arthritis and Rheumatism</i> , 2005, 52, 2519-2520.	6.7	48
137	Distribution of HLA-B27 subtypes in Sardinia and continental Italy and their association with spondylarthropathies. <i>Arthritis and Rheumatism</i> , 2005, 52, 3319-3321.	6.7	67
138	Increased Bcl-2/p53 ratio in human osteoarthritic cartilage: a possible role in regulation of chondrocyte metabolism. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 217-221.	0.9	29
139	The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension. <i>Current Medical Research and Opinion</i> , 2005, 21, 327-332.	1.9	43
140	Anti-cyclic citrullinated peptide autoantibodies measured by an automated enzyme immunoassay: Analytical performance and clinical correlations. <i>Clinica Chimica Acta</i> , 2005, 355, 137-144.	1.1	15
141	Metabolic Activity of Chondrocytes in Human Osteoarthritis as a Result of Cell-extracellular Matrix Interactions. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 34, 9-12.	3.4	7
142	Reliability and validity of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index in Italian patients with osteoarthritis of the knee. <i>Osteoarthritis and Cartilage</i> , 2003, 11, 551-560.	1.3	223
143	Structural and oxidative modifications of erythrocyte ghosts in patients with primary biliary cirrhosis: relation with the disease stage and effect of bile acid treatment. <i>European Journal of Clinical Investigation</i> , 2003, 33, 868-874.	3.4	7
144	The pathophysiology of osteoarthritis. <i>Aging Clinical and Experimental Research</i> , 2003, 15, 364-372.	2.9	153

#	ARTICLE	IF	CITATIONS
145	Leucocytoclastic vasculitis as onset symptom of ulcerative colitis. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 785-786.	0.9	28
146	Microscopic polyangiitis associated with primary biliary cirrhosis. <i>Journal of Rheumatology</i> , 2003, 30, 2710-2.	2.0	17
147	Increased expression of nerve growth factor (NGF) and high affinity NGF receptor (p140 TrkA) in human osteoarthritic chondrocytes. <i>British Journal of Rheumatology</i> , 2002, 41, 1413-1418.	2.3	125
148	Mitochondrial Disease Mimicking Polymyositis: A Case Report. <i>Clinical Rheumatology</i> , 2002, 21, 411-414.	2.2	5
149	Chondrocytes-ECM Interactions in Human Osteoarthritis. <i>Advances in Experimental Medicine and Biology</i> , 1999, 455, 413-417.	1.6	3
150	Chondrocyte phenotyping in human osteoarthritis. <i>Clinical Rheumatology</i> , 1998, 17, 99-104.	2.2	33
151	Clinical diagnosis found in patients with Raynaud's phenomenon: a multicentre study. <i>Rheumatology International</i> , 1998, 18, 17-20.	3.0	36
152	Coexisting Psoriatic Arthritis, Gout, and Chondrocalcinosis: CASE REPORT. <i>Scandinavian Journal of Rheumatology</i> , 1998, 27, 306-309.	1.1	15
153	Isolated thrombocytopenia associated with low dose methotrexate therapy. <i>Clinical Rheumatology</i> , 1997, 16, 429-430.	2.2	9
154	Carpal tunnel syndrome: A review. <i>Clinical Rheumatology</i> , 1997, 16, 596-603.	2.2	6
155	Isolated sternoclavicular joint arthritis in heroin addicts and/or HIV positive patients: Three cases. <i>Clinical Rheumatology</i> , 1993, 12, 422-425.	2.2	24
156	Early alteration of synovial membrane in osteoarthrosis. <i>Clinical Rheumatology</i> , 1988, 7, 214-219.	2.2	17
157	Present Status and New Perspectives in Non-Steroidal Anti-Inflammatory Drugs Therapy. <i>Scandinavian Journal of Rheumatology</i> , 1987, 16, 75-83.	1.1	1
158	The Acute Phase Protein Profile in Inflammatory Arthropathies. <i>Scandinavian Journal of Rheumatology</i> , 1987, 16, 90-93.	1.1	3
159	Monoclonal antibody investigation in rheumatoid arthritis: presence of a T cell subpopulation bearing a double marker. <i>Clinical Rheumatology</i> , 1984, 3, 137-144.	2.2	4
160	Protein measurement of inflammation. <i>Research in Clinic and Laboratory</i> , 1981, 11, 223-7.	0.3	1